URTESTE S.A.

Urteste S.A. Established in 2019 is a pioneering biotechnology company focused on revolutionizing early cancer detection with innovative, non-invasive diagnostics. Urteste develops in vitro diagnostic (IVD) solutions using proprietary synthetic peptides to detect cancer-related enzymatic activity in urine samples. The technology offers a breakthrough in early detection across 12 types of cancer: pancreatic, breast, prostate, lung, liver, colorectal, kidney, endometrial, ovarian, bile ducts, stomach, and brain.

Our core mission is to enhance early cancer detection, ultimately improving patient outcomes and reducing healthcare costs associated with late-stage diagnosis. By offering a rapid, non-invasive, and highly sensitive testing method, our technology has the potential to transform screening protocols across most common cancers.

Our flagship project - Panuri - a groundbreaking in vitro diagnostic test for early pancreatic cancer detection. The test is analyzing urine samples for proteolytic enzyme activity linked to early tumor development. Preliminary clinical studies demonstrated 95.6% sensitivity and 95.5% specificity, underscoring its potential for early detection when treatment is most effective.

Urteste’s robust research and development efforts are supported by a highly skilled team of scientists, medical professionals, and industry experts. We are publicly listed on the Warsaw Stock Exchange (WSE: URT). Our commitment to innovation, scientific excellence, and commercialization ensures that we remain at the forefront of laboratory medicine, bringing cutting-edge diagnostic solutions to market.